

TMD Lab Co., Ltd

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	TMD Lab Co., Ltd
○ Representative	Mi-Lan Kang
○ Establishment year	October 15, 2018
○ Specialized Field	Medical Devices for Insertion into the Human Body
○ Address	(HQ) 31, Gwangnaru-ro 8-gil, Seongdong-gu, Seoul, Republic of Korea
○ Home page	- Homepage: www.tmdlabor.com
○ Enterprise Brief Introduction	TMD LAB is a corporate established to research and develop new material medical devices and cutting-edge biomedicine, with shape memory polymer and cell-derived nanovesicle base technology. In regard to shape memory polymer base technology, we have obtained the non-exclusive license from the industrial-educational cooperation group of Yonsei University along with the right to develop and make sales on a product with SMP. We also have secured the property right for the CNV base technology through patent application from TMD LAB itself. TMD LAB is on its way of preparing R&D and licensing on arthritis medicine based on CNV technology, and the human insertion stent with a new concept based on SMP base technology.
○ Product and Pipeline Introduction	<ol style="list-style-type: none"> 1. External Vascular Support: (1) Arteriovenous fistula surgery (Shunt surgery of connecting an artery and a vein near the skin, for a patient with chronic renal insufficiency under frequent hemodialysis treatments, so that the vein is expanded to have sufficient amount of blood flow, and is strengthened like the artery) 2. (2) Coronary artery bypass surgery (Surgery which creates a bypass for bloodstream 3. provided to the heart, by connecting a duct (a radial artery near the wrist, or a saphenous vein in the leg), as an alternative to the narrow coronary artery) 4. Lacrimal duct stent (Maintaining the lacrimal duct diameter by self-expansion, after being inserted into the point of nasolacrimal duct obstruction) 5. Rhinoplasty Implant: Prevention of slipping and fixing effects, inhibition of biofilm formation, prevention of see-through.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Series A round Investment (5.77 billion won) secured / Applied for 8 foreign journal papers, 6 domestic patents, and 2 PCTs / External Vascular support (designated as a newly developed medical device), Lacrimal stent (registration at MFDS in progress)